TransCode Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company’s lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Frequently asked questions
To buy TransCode Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for TransCode Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for TransCode Therapeutics Inc. is RNAZ:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
TransCode Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade TransCode Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, TransCode Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include TransCode Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like TransCode Therapeutics Inc..